Free Trial

RAPT Therapeutics (RAPT) News Today

$3.95
-0.12 (-2.95%)
(As of 05/29/2024 ET)
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of "Hold" by Analysts
RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been assigned a consensus rating of "Hold" from the thirteen ratings firms that are covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation and four have issued a buy rec
Wolfe Research Reaffirms "Peer Perform" Rating for RAPT Therapeutics (NASDAQ:RAPT)
Wolfe Research reiterated a "peer perform" rating on shares of RAPT Therapeutics in a research report on Tuesday.
TimesSquare Capital Management LLC Invests $12.53 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)
TimesSquare Capital Management LLC purchased a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 504,340 shares of the company's sto
Guggenheim Lowers RAPT Therapeutics (NASDAQ:RAPT) to Neutral
Guggenheim cut RAPT Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday.
RAPT Therapeutics (NASDAQ:RAPT) Earns Neutral Rating from HC Wainwright
HC Wainwright restated a "neutral" rating on shares of RAPT Therapeutics in a report on Wednesday.
3 Biotech Stocks to Dump Before They Go to Zero
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve brokerages that are presently covering the company, Marketbeat reports. Six analysts have rated the stock with a hold recommendation and six have issued a buy recommend
Short Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 32.5%
RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 3,300,000 shares, a growth of 32.5% from the February 29th total of 2,490,000 shares. Based on an average daily trading volume, of 1,210,000 shares, the days-to-cover ratio is presently 2.7 days.
RAPT Therapeutics (NASDAQ:RAPT) Price Target Cut to $13.00
JPMorgan Chase & Co. reduced their price target on shares of RAPT Therapeutics from $15.00 to $13.00 and set a "neutral" rating on the stock in a research report on Wednesday.
RAPT Apr 2024 10.000 put
RAPT Oct 2024 5.000 call
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Bought by Braidwell LP
Braidwell LP grew its holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 10.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,082,512 shares of the company's stock after acquiring an addi
Fmr LLC Grows Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)
Fmr LLC increased its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 7.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,499,293 shares of the company's stock after a
RAPT May 2024 17.500 put
UBS Downgrades RAPT Therapeutics (RAPT)
RAPT Therapeutics (NASDAQ:RAPT) Downgraded by UBS Group to Neutral
UBS Group cut shares of RAPT Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $61.00 to $10.00 in a report on Thursday.
Rapt Therapeutics just downgraded at Leerink, here's why
What's Going On With RAPT Therapeutics Stock On Wednesday?
Barclays Lowers RAPT Therapeutics (NASDAQ:RAPT) Price Target to $13.00
Barclays reduced their target price on RAPT Therapeutics from $35.00 to $13.00 and set an "overweight" rating for the company in a report on Wednesday.
Get RAPT Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.

The only AI company to buy (Ad)

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

RAPT Media Mentions By Week

RAPT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RAPT
News Sentiment

0.75

0.78

Average
Medical
News Sentiment

RAPT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RAPT Articles
This Week

4

2

RAPT Articles
Average Week

Get RAPT Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:RAPT) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners